VERTEX PHARMACEUTICALS INC / MA Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss of $8.40 million as of 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss · last filed 2026-05-05
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $8.40M.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $9.70M.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $9.90M.
- 2025-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $6.20M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss |
|---|---|
| 2026-03-31 | $8.40M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $9.70M 10-K · filed 2026-02-13 |
| 2025-09-30 | $9.90M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $6.20M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $7.60M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $19.10M 10-K · filed 2025-02-13 |
| 2024-09-30 | $68.60M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $382.40M 10-Q · filed 2024-08-02 |
| 2024-03-31 | $400.00K 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |